Topics
plainPlace
myelomaDisease
magnetic resonance imagingTopical concept
plasmacytomaDisease
carcinomaDisease
radiographyTopical concept
Positron emission tomography with 2-deoxy-2-[18]fluoro-D-glucose (FDG-PET) imaging has been extensively used to detect occult metastatic malignant lesions in patients with carcinoma. We describe its use in three patients with multiple myeloma, each representing a particular clinical situation in which this imaging modality offered advantages over plain radiography, computerized tomography or magnetic resonance imaging. FDG-PET provides a whole body image showing sites of occult disease. This is of particular value in patients with non-secretory myeloma, solitary plasmacytoma or for those that relapse with focal disease following autologous or allogeneic stem cell transplantation.</p
Multiple myeloma (MM) is the second most common hematological malignancy. Although it can affect dif...
Multiple myeloma (MM) is the second most common hematological malignancy after non-Hodgkin's lymphom...
International audienceMultiple myeloma is a malignant B-cell neoplasm that involves the skeleton in ...
Multiple myeloma (MM) is a hematological neoplasm characterized by the clonal proliferation of malig...
The International Myeloma Working Group consensus aimed to provide recommendations for the optimal u...
Multiple myeloma is the second most common hematologic malignancy and occurs most commonly in elderl...
Multiple myeloma (MM) is a plasma cell malignancy and is characterized by the presence of lytic bone...
Recent advances in the diagnosis and treatment of multiple myeloma (MM) have highlighted the importa...
International audienceSerum markers and bone marrow examination are commonly used for monitoring the...
Abstract Background Despite the significant upgrading in recent years of the role of 18F-FDG PET/CT ...
Conventional radiographic skeletal survey has been for many years the gold standard to detect the oc...
Serum markers and bone marrow examination are commonly used for monitoring therapy response in multi...
New imaging techniques have been introduced to assess the extent and severity of disease in multiple...
Multiple myeloma (MM) is the second most common hematological malignancy. Although it can affect dif...
Multiple myeloma (MM) is the second most common hematological malignancy after non-Hodgkin's lymphom...
International audienceMultiple myeloma is a malignant B-cell neoplasm that involves the skeleton in ...
Multiple myeloma (MM) is a hematological neoplasm characterized by the clonal proliferation of malig...
The International Myeloma Working Group consensus aimed to provide recommendations for the optimal u...
Multiple myeloma is the second most common hematologic malignancy and occurs most commonly in elderl...
Multiple myeloma (MM) is a plasma cell malignancy and is characterized by the presence of lytic bone...
Recent advances in the diagnosis and treatment of multiple myeloma (MM) have highlighted the importa...
International audienceSerum markers and bone marrow examination are commonly used for monitoring the...
Abstract Background Despite the significant upgrading in recent years of the role of 18F-FDG PET/CT ...
Conventional radiographic skeletal survey has been for many years the gold standard to detect the oc...
Serum markers and bone marrow examination are commonly used for monitoring therapy response in multi...
New imaging techniques have been introduced to assess the extent and severity of disease in multiple...
Multiple myeloma (MM) is the second most common hematological malignancy. Although it can affect dif...
Multiple myeloma (MM) is the second most common hematological malignancy after non-Hodgkin's lymphom...
International audienceMultiple myeloma is a malignant B-cell neoplasm that involves the skeleton in ...
Add to ORKG